The key to the use of medicinal drug treatments has been determined

Researchers from Cambridge University, UK, have discovered why the treatment of ovarian cancer is only effective in half of patients with the disease.

Paclitaxel is a drug that causes cancer cells to self-destruct, but university researchers have found that in patients who lack a specific protein, the drug will not work.

The UK Cancer Research Center and the Medical Research Council funded the study, saying this will help ensure that the drug will be given to people who will help them.

Sad egg cancer is a very difficult disease to predict early(Photo: SPL, BBC )

Every year, in the UK, there are 7,000 cases of ovarian cancer.

Paclitaxel is part of a family of drugs called taxanes. It is extracted from yew tree. Researchers from the Cambridge Research Institute studied ovarian cancer cells and data of 20 patients. They found that patients who did not respond to paclitaxel had lower levels of TGFBI protein in pre-treatment samples.

Further analysis showed higher rates of cancer cells after treatment in patients with high levels of TGFBI protein.

Dr. James Brenton, lead researcher, said: 'The TBFBI protein is lost in about one-third of the progenitor cells and it is possible that this protein has been used as a biomarker in selecting patients. Any reaction to this drug. Our findings not only create hope in improving the treatment of ovarian cancer and it can also lead to an improvement in the effectiveness of the drug taxene used in the treatment of cancer. lung and breast cancer. '

Personalized medicine

Dr. Ahmed Ashour Ahmed of the research team said: 'Our research has shown that some proteins located around cancer cells such as TGFBI proteins, for example, send signals to microcapsules and walls. The main part of a cell, makes the cells perceive paclitaxel. "

Decoding the signals sent to the microtubule will help detect many new therapies that can simulate encrypted signals. This will lead to a significant improvement of the reaction with paclitaxel.

"We are entering an era of cancer treatment in which drugs are focused primarily on patients who benefit from these types of cancer," said Professor Herbie Newell of the British Cancer Research Center. This medicine the most. The method of using personalized drugs also means that new treatments will be more effective and have fewer side effects. This is especially important for many types of cancer-like diseases because it is a very difficult disease to treat. '

Uyen Nhi